Sanuwave cuts Q2 2026 revenue guidance to $8.5-9.5M on Ultramist market disruption

SANUWAVE Health, Inc.

Revenue guidance for Q2 2026 reduced to $8.5-$9.5M from prior guidance provided on May 13.
Downgrade driven by CMS reimbursement clawbacks causing wound care practice closures and cannibalization from used Ultramist systems.
Applicator consumables on pace for record quarterly unit volume in Q2.
CEO Morgan Frank sees positive applicator outlook but near-term headwinds from capital sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.